UNSPSC 51272901: Propofol

This classification denotes a sedative and hypnotic with the molecular formula C12H18O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YI7VU623SF, chemically known as 2,6-dipropan-2-ylphenol but generally known as propofol, which bears US NIH Compound Identifier 4943. European Medicines Agency schedules Propofol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10116MIG.

UNSPSC 51272901 Propofol is a Commodity code that nominally covers a single anesthetic agent, but recent state and local procurement activity under this code shows substantial mismatch with the specific product name. Instead, state and local governments are soliciting a broader range of pharmaceuticals, controlled substances, and over-the-counter products through this classification — including naloxone, generic multi-source medications, and direct-to-manufacturer prescription programs. The issuing bodies span state health and human services agencies, county health departments, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Department of Administration (through MMCAP) appear as active buyers in the current market. Work solicited includes competitive bidding for naloxone and drug deactivation systems with quarterly delivery requirements, cooperative purchasing agreements for generic pharmaceuticals across multiple states, and exploratory requests for information on direct contracting models between state pharmacy benefit programs and manufacturers.

Activity concentrates in Florida and Minnesota, with multistate scope through cooperative purchasing vehicles like MMCAP that serve Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription contracting; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson). The MMCAP procurement weights price competitiveness at seventy-five percent and requires vendors to maintain commercial general liability coverage of $5 million per occurrence and network security and privacy liability of $2 million.